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Is aspirin a powerful weapon against cardiovascular disease? Studies by 
a BUSM research team headed by Daniel Deykin, M.D., aim to answer this 
question, which has been the subject of intense debate within the medical 
community. See story on page 3. 
The effectiveness of more rigid drunk-driving laws in Maine and Massachusetts is being 
examined by researchers at BUSM. 
Are drunk-driving laws saving lives? 
BUSM research team seeks answers 
BUSM researchers 
seek to develop 
vaccine to protect 
against gonorrhea 
Each year there are between two 
and three million new cases of gon-
orrhea in the United States. Not all of 
the cases take the form of sexually 
transmitted diseases that most peo-
ple think of when they hear the term. 
Neisseria gonorrhoeae, as the 
bacteria that cause gonorrhea are 
called, also is one of the major 
causes of pelvic inflammatory dis-
ease, a condition that often strikes 
women in their reproductive years, 
resulting in infertility in 15 percent of 
the cases. The bacteria also cause 
disseminated gonorrhea, a less com-
mon blood-borne form of the disease 
that can produce painful and infected 
joints, skin lesions and sometimes in-
fection of the heart valves. 
While all of these conditions gen-
erally can be treated with penicillin, 
increasingly there are strains emerg-
ing that are resistant to the drug. 
And, for example, in the case of pel-
vic inflammatory disease, even when 
the antibiotics erradicate the infec-
tion, the damage to the female's re-
productive tract, which frequently re-
sults from complications of the 
disease, may be permanent. In addi-
tion, one of the challenging factors 
involved in treating the disease is 
that often both males and females 
appear to have no symptoms or 
continued on page 5 
On a recent winter afternoon, as a 
13-year-old Rhode Island boy was 
walking to a sporting goods store 
near his home, he was struck by a 
car. Police charged the driver of the 
car with driving under the influence 
of alcohol. The boy, who was 
knocked 90 feet away from the auto, 
died instantly. 
This teen-ager is one of between 
16,000 and 30,000 people who die 
each year in car accidents involving 
drunk drivers. Officials estimate that 
one-third of all drivers in fatal 
crashes have blood alcohol levels of 
at least .10 at the time of the acci-
dent (the equivalent of about five 
drinks on an empty stomach). 
In an attempt to reduce these alco-
hol-related tragedies, and under tre-
mendous pressure from such lobby-
ing groups as Mothers Against Drunk 
Driving and Remove Intoxicated Driv-
ers, 34 states in the past two years 
have passed tough laws to deter 
drunk driving. 
Many questions now are being 
raised about the effectiveness of 
these laws. Do people in states with 
strict drunk-driving legislation actually 
drive less after drinking? Are there 
continued on page 2 
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Drunk-driving... 
continued from page 1 
fewer alcohol-related accidents in 
these states? 
In an attempt to determine if these 
laws actually are saving lives and if 
the laws have a sustained effect on 
drunk-driving, researchers at the 
School of Public Health at Boston 
University School of Medicine are 
conducting a concentrated study on 
the effects of drunk-driving legislation 
passed in Maine and Massachusetts. 
Originally, when the study began 
in 1981, SPH researchers planned to 
concentrate only on the drunk-driving 
legislation passed in Maine, which 
when enacted in 1981, was dubbed 
"the toughest drunk-driving law in the 
nation." They planned to use Massa-
chusetts, which at that time had less 
strict drunk-driving laws, as a state 
with which to measure the results of 
the Maine law. 
With the recent passage of more 
strict Massachusetts legislation, the 
study has been expanded to evalu-
ate the effectiveness of the laws in 
both states, using other states in 
New England as the control. 
While the drunk-driving laws in 
Massachusetts and Maine are similar 
in some respects, they differ signifi-
cantly in others. The Massachusetts 
law, passed in 1982, concentrates on 
increasing drunk-driving penalties, 
particularly for repeat offenders. 
Maine's legislators both increased 
the penalties and made them man-
datory, but also took steps to expe-
dite the judicial process and increase 
the likelihood of conviction. These 
steps include a provision making op-
erating under the influence of alcohol 
a civil offense, requiring the state 
only to establish a preponderance of 
evidence to convict drunk drivers, in-
stead of proving guilt beyond a rea-
sonable doubt as required in other 
states. Also, the legislation made it il-
legal to drive with a blood-alcohol 
level of .10 or higher. Previously, 
blood-alcohol levels were presump-
tive evidence that allowed offenders 
to contest this charge in court. 
Officials of both states hoped 
these changes would reduce plea 
bargaining, would force more speedy 
trials and would act as a clear deter-
rent to the potential drunk-driver. 
Before Maine's law went into ef-
fect, the drunk-driving problem there 
was similar to that in virtually every 
other state in the nation. About 60 
percent of all Maine traffic accidents 
were alcohol-related, resulting in 
about 200 deaths yearly. 
"In the summer of 1981, when we 
became aware that this new law 
might be passed in Maine, we con-
tacted the governer's office there to 
determine if we could evaluate the 
law's effect. They were extremely in-
terested," said Ralph W. Hingson, 
Sc.D., an associate professor of pub-
lic health (social and behavioral sci-
ences) at SPH and principal investi-
gator of the study. 
The researchers then devised a 
survey to be used in 1,000 random 
telephone interviews in Maine. They 
also planned 1,000 interviews with 
residents in Massachusetts, which at 
the time lacked the more strict drunk-
driving laws, to use as a comparison 
group. The researchers decided to 
conduct the survey once a year for 
three years to determine whether the 
new law would have a sustained ef-
fect. 
The survey included such ques-
tions as: 
• "How likely do you think it is that 
drunk drivers would be arrested in 
your state?" 
• "How often would these drunk 
drivers be convicted?" 
• "How often do you drive after 
drinking?" 
Other factors being investigated by 
Hingson's team include the statistics 
in these states on drunk-driving ar-
rests and convictions, fatal accidents 
and deaths due to accidents. 
Researchers who in the past have 
studied the effects of drunk-driving 
laws are "very skeptical about the 
ability of the drunk-driving laws to 
make a difference" over longer peri-
ods of time, according to Hingson. 
A 1981 report by the Insurance In-
stitute for Highway Safety concluded: 
"None of the countermeasure ap-
proaches devised and implemented 
(by states) to deter these drivers has 
been found by competent research 
to have a permanent influence on re-
ducing deaths resulting from crashes 
by drunk-drivers." 
In addition, a recent study by Hing-
son's research team showed that the 
1981 legal drinking age change from 
18 to 20 in Massachusetts has had 
only modest effects on the drinking 
and driving behavior of the state's 
teen-agers. The two-year study 
showed that, in comparison to teen-
agers in New York state, there was 
no decline in overall fatal crashes 
among 16- to 19-year-olds in Massa-
chusetts. 
Because Maine's law went into ef-
fect only weeks after BUSM re-
searchers became involved in the 
study in the summer of 1981, the 
team had to work quickly to collect 
their first set of survey data to use as 
a pre-law change baseline. 
Working together with Maine offi-
cials, the team was able to complete 
their calls that August. 
The second survey blitz was com-
pleted in the summer of 1982, and 
the researchers are conducting the 
questioning again this summer. 
While the interviews began merely 
days after the research proposal was 
hatched, funding for the project came 
much more slowly. 
In August 1981, Maine officials do-
nated a starter fund with which the 
researchers were able to begin their 
first Maine survey. 
While the researchers waited for 
grants from other organizations to 
continue their work, BUSM Dean 
John I. Sandson and Norman A. 
Scotch, Ph.D., director of SPH and 
chairman of the Department of So-
cio-medical Sciences and Commu-
nity Medicine, donated some School 
money to keep the project alive. 
"The School of Medicine and the 
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investigated by BUSM research team 
School of Public Health went out on 
a limb for us. Drs. Sandson and 
Scotch felt that this was an important 
project and trusted that we would 
eventually get the funds to complete 
it. I was very impressed with their 
willingness to do that," said Hingson. 
Finally by June of last year, the 
National Institute of Alcoholism and 
Alcohol Abuse; the Milbank Fund, a 
private philanthropic institution; the 
U.S. Department of Transportation, 
and the Commonwealth Fund all 
contributed to the project. 
Hingson currently is collecting data 
from a control group made up of 
other New England states to com-
pare with Massachusetts residents' 
drunk-driving perceptions and statis-
tics. He also is working to gain addi-
tional funding to extend the study to 
evaluate the Massachusetts law over 
time. 
"We are providing ongoing infor-
mation to officials in the states in-
volved in our study who are inter-
ested in what impact their law is 
having on public perceptions of driv-
ers," said Hingson. 
In addition to Hingson and Scotch, 
other researchers involved in the 
project are: Allan R. Meyers, Ph.D., 
an associate director of SPH and an 
assistant professor of public health 
(health systems); Thomas W. Man-
gione, Ph.D., a SPH adjunct associ-
ate professor of public health (epide-
miology and biostatistics); David 
Kovenock, Ph.D., director of the So-
cial Science Research Institute at the 
University of Maine in Orono; Timo-
thy Heeren, B.A., a SPH instructor of 
public health (epidemiology and bios-
tatistics); and Suzzette Morelock, a 
SPH research assistant. 
—Paul D. Vaskas 
Suggested Further Readings 
1. Ross, H.L: Deterring the Drinking Driver: 
Legal Policy and Social Control. Lexington 
Books, Lexington, Mass., 1982. 
2. Hingson, R. et al: Impact of legislation rais-
ing the legal drinking age. Am J of Pub 
Health. 73: 163-170, 1983. 
In recent years, studies suggesting 
that aspirin might be a potent 
weapon against cardiovascular dis-
ease have stirred intense public in-
terest. 
It isn't difficult to imagine why that 
idea has elicited interest. Here is an 
inexpensive drug that is available at 
every corner grocery or drugstore 
and that has been around long 
enough for the medical community to 
conclude with considerable certainty 
that for most people it has no major 
side effects (although it may cause 
gastrointestinal bleeding in some 
people). 
Unfortunately, though, the matter 
of aspirin's effectiveness against car-
diovascular disease is by no means 
resolved. In fact, the issue still is 
being hotly debated within the medi-
cal community. 
At this point, there is no way of 
knowing when the debate will be 
concluded and what its outcome will 
be. But research being carried out by 
investigators at Boston University 
School of Medicine shows strong 
promise of helping to bring about an 
early resolution of the aspirin issue. 
The research, which is supported 
with funds from the National Heart, 
Lung and Blood Institute and the 
Veterans Administration, is being 
carried out under the direction of 
Daniel Deykin, M.D. Deykin is the 
Maurice B. Strauss Professor of 
Medicine at BUSM and Tufts Univer-
sity School of Medicine, and is chief 
of medicine at the Boston Veterans 
Administration Medical Center, which 
serves as a teaching site for both 
medical schools. 
Deykin, who oversees a wide vari-
ety of research related to the body's 
circulatory system, said that recent 
findings about aspirin's behavior in 
the bloodstream have helped to bring 
the dispute over the drug into better 
focus. 
The key factor, said Deykin, is the 
effect that aspirin has on both the 
platelets—those tiny elements in the 
blood that are the main components 
Daniel Deykin, M.D., seeks clues to understanding aspirin's role in heart disease. 
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of blood clots—and the blood ves-
sels. 
"Aspirin causes platelets to be-
come less active, and if you're trying 
to prevent the platelet buildups that 
can lead to coronary occlusion or to 
a stroke, that's good. But the aspirin 
also seems to make changes in the 
blood vessel walls that may not be 
so good," said Deykin. 
Ironically, both kinds of interactions 
result from the fact that aspirin 
chemically modifies a certain type of 
enzyme, thereby preventing the en-
zyme from carrying out its normal 
function as a catalyst. 
In the platelets, this enzyme's role 
is to trigger a process that results in 
the production of a substance that 
tends to make the platelets "sticky." 
This substance, called thromboxane, 
can cause platelets to build up on a 
blood vessel wall, said Joseph A. 
Jakubowski, Ph.D., a research asso-
ciate at BUSM and one bf Deykin's 
collaborators. If such buildups be-
come large enough, he added, the 
result may be a coronary occlusion. 
In the cells that line blood vessel 
walls, however, this same enzyme 
leads to the production of another 
substance called prostacyclin, which 
tends to keep platelets from collect-
ing on the vessel walls. 
If there were no more to the issue 
than that, the case for aspirin's value 
as a protective agent against cardio-
vascular disease might look weak. 
A key question, however, said 
Deykin, is whether there is some 
dose level at which aspirin will "sup-
press activity in the platelets while 
largely sparing the blood vessels 
where the thrombi—the platelet 
buildups—commonly occur." In fact, 
Deykin and his associates have un-
covered convincing evidence that 
such a dosage does exist. 
"In a series of animal experi-
ments," said Jakubowski, "we found 
that if we used an aspirin dose of 
one milligram per kilogram of body 
weight—which would be the equiva-
lent of an adult taking one baby aspi-
rin—the production of thromboxane 
by platelets is strongly suppressed." 
On the other hand, he went on, 
aspirin at that dosage did not sup-
press the production of prostacyclin 
in the animals' arterial walls. 
According to Deykin, the next step 
in trying to pursue the low-dosage 
hypothesis will be another series of 
experiments involving primates, to be 
carried out in collaboration with 
William Hollander, M.D., a professor 
of medicine and biochemistry at 
BUSM. In the experiments, which are 
expected to take approximately a 
year to conduct, the animals will be 
fed a diet that predisposes them to 
atherosclerosis, and some will be 
given aspirin at low doses. Then the 
groups of animals will be monitored 
to see if the low-dose aspirin helps 
to prevent the platelet buildups that 
are often preludes to coronary occlu-
sion and stroke. 
Deykin cautioned, however, that 
even if the project yields the positive 
results that the preliminary research 
seems to point to, it still will not pro-
vide definitive indications on whether 
a low-dose aspirin regimen also 
would work in humans. However, he 
said, such results would provide a 
strong inducement to move on to 
clinical trials involving patients at se-
rious risk of developing coronary dis-
ease. 
Another research avenue being 
pursued by Deykin and his associ-
ates is in providing new information 
about some of the basic mechanisms 
underlying the onset of arterial dis-
ease. 
Several years ago, said Deykin, he 
and his fellow investigators noted 
that arachidonic acid—a fatty acid 
that is one of the key factors in the 
process leading to the buildup of 
platelets in blood vessels—is highly 
concentrated in certain components 
of platelets. 
"While looking for the enzymes 
that might account for this accumula-
tion of arachidonic acid," he said, 
"we have found a new enzyme, 
one that works by a method that 
seems to be different from any other 
platelet enzyme." 
In most interactions in the platelet 
between enzymes and arachidonic 
acid, the acid first is freed from its 
storage place within the platelets; 
once freed, other enzymes go to 
work on it to produce a variety of 
substances related to the functions 
of the platelets—including thrombox-
ane, which makes platelets stick to 
the blood vessels and to one an-
other. 
This new enzyme, called arachi-
donoyl-transacylase, however, 
seems to transfer the arachidonic 
acid to certain components of the 
platelet without the acid's first having 
to be freed from those portions of the 
platelets where it is normally stored. 
"That's a new kind of process," 
said Ruth M. Kramer, Ph.D., an as-
sistant professor of biochemistry at 
BUSM and another of Deykin's col-
laborators. "Another fascinating thing 
about this enzyme is that it's highly 
specific. We've found in some of our 
lab work that it can discriminate be-
tween arachidonic acid and com-
pounds that, chemically, are virtually 
identical." 
Such interesting properties, said 
Deykin, do not yet shed much light 
on such questions as what the en-
zyme's role is in making the body 
prone to coronary disease. He 
added, however, that the preliminary 
findings are intriguing enough to 
make the enzyme well worth further 
scrutiny. 
"Now that we've described how it 
works," he said, "we're going to try to 
purify it, to identify its location within 
the platelets and elsewhere, and to 
find out how it is regulated." 
—Richard P. Anthony 
Suggested Further Readings 
1. Deykin, D.: Thrombosis and antithrombotic 
therapy. In: Harrison's Principles of Internal 
Medicine: Update II. Isselbacher, et al 
(eds.), McGraw-Hill, pp 51-73, 1982. 
2. Marcus, A.J.: The role of lipids in platelet 
function: with particular reference to the ar-
achidonic acid pathway. J Lipid Res. 79: 
793-826, 1978. 
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continued from page 7 
don't recognize symptoms that they 
might have, and the spread of the 
disease continues. 
The many challenges of diagnos-
ing, treating and preventing infec-
tions caused by the different strains 
of Neisseria gonorrhoeae are the fo-
cus of research being conducted by 
Boston University School of Medicine 
faculty member Peter A. Rice, M.D., 
as he and his research team seek to 
develop a vaccine that could be used 
to immunize humans against the 
harmful effects of gonorrhea-causing 
bacteria, also called gonococci. Rice 
is an associate professor of medicine 
at the School and director of the 
Clinical Immunology Laboratory at 
Boston City Hospital. His work in 
gonorrhea, which is conducted in the 
Maxwell Finland Laboratories for In-
fectious Diseases, is supported by 
the National Institutes of Health, al-
though he is seeking additional fund-
ing. 
For seven years. Rice and his col-
This electron micrograph shows a Neisseria 
gonorrhoeae cell. The cell has been stained to 
show the components of the cell wall: the inner 
wall, or cytoplasmic membrane (CM. ) ; the 
outer membrane (O.M.); and peptidoglycan 
(P.G.), the substance that lies between the two 
walls. (Photo by Floyd Craft) 
leagues have been studying the gon-
ococcal organism at the immuno-
chemical level in an effort to under-
stand how gonococci interact with 
the host (or human body), what 
changes take place to cause the 
bacteria to produce different manifes-
tations of the disease and how the 
human body interacts uniquely with 
the different strains. 
The researchers are, in turn, put-
ting this basic research to practical 
use in other ongoing laboratory ex-
periments as they work to develop 
methods that would be useful in 
rapid diagnosis of the disease and a 
vaccine or group of vaccines capable 
of immunizing humans against one 
or more of the diseases caused by 
Neisseria gonorrhoeae. It is the re-
searchers' hope that humans could 
be protected, if not from all forms of 
gonorrhea, at least from those that 
are invasive and result in clinically 
more severe infection. 
"We are trying to pinpoint what an-
tigens (or antibody-provoking sub-
stances) would be most useful for 
immunization," Rice said. "And, while 
vaccine trials in humans currently are 
being performed by other research 
teams, the antigens that are being 
employed by those investigators 
have been chosen because they 
may enable human hosts to produce 
antibodies in their genital secretions 
that will prevent the organism from 
securing a foothold. Our attention 
presently is focused on a vaccine 
that will protect humans from inva-
sion by gonococci beyond the genital 
surfaces." 
Rice also is conducting similar in-
vestigations to test the feasibility of 
developing an immunization program 
to protect humans against non-typea-
ble Haemophiius infiuenzae (NTH), 
which is a major contributor to the 20 
million cases of otitis media or mid-
dle ear infections that occur each 
year, primarily in children. This bac-
teria also causes sinusitis in adults 
and children, and pneumonia, espe-
cially in the elderly or hospitalized. 
Rice is conducting the influenza 
The challenge of preventing infections caused 
by gonococci is one focus of research being 
conducted by Peter A. Rice, M.D., shown 
above with laboratory technologist Sunita 
Gulati. 
Studies in cooperation with Steven I. 
Pelton, M.D., an associate professor 
of pediatrics at the School and asso-
ciate director of pediatrics at Boston 
City Hospital, and Aubrey Milunsky, 
MB.B.Ch., professor of pediatrics 
and director of the Department of 
Pediatrics' Section on Medical Ge-
netics. 
One of the key elements in the de-
velopment of the gonorrhea vaccine 
is a group of antigens known as lipo-
polysaccharides (LPS). 
"An LPS vaccine, as it stands now, 
would be quite toxic—people might 
get sicker from the vaccine than from 
some forms of the infection. But, we 
are preparing a derivative of the sub-
stance that would be less toxic," Rice 
said. 
Lipopolysaccharides are one of the 
major structures found in the outer 
membranes of many bacteria, includ-
ing gonococci. In laboratory tests, 
the researchers have found that LPS 
can provoke the production of an an-
tibody in humans that assists in kill-
ing the invasive types of gonococcal 
organisms. 
"The evidence, indirect as it is at 
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this time, suggests that these anti-
bodies, which are directed against 
LPS antigens, might be useful in pro-
tecting humans against invasive 
forms of the infection if, in fact, the 
antibody can effectively recognize 
the organism and, together with a 
group of other blood components 
called complement, kill it directly or 
facilitate its killing by the host's white 
blood cells before the gonococci 
have a chance to multiply and 
spread," Rice said. 
The researchers also are working 
to detoxify LPS antigens so that 
these antigens would be more suita-
ble for human use, while still pre-
serving their antibody-producing 
properties. "We also want to deter-
mine what mix of antigens might be 
needed to stimulate antibodies effec-
tive against a broad array of organ-
isms," Rice said. 
Another class of antigens under 
study by Rice and his research team 
is known as outer membrane pro-
teins. One study conducted by the 
researchers indicates that naturally 
occurring antibodies directed against 
these antigens in normal healthy in-
dividuals may, in fact, protect the 
gonococcal organism and be a liabil-
ity to the host. These antibodies pre-
vent the host from being able to kill 
the invading organism by screening 
out or blocking access of the killing 
antibodies to their binding sites on 
the surface of the organism—in other 
words, the host turns on itself. "We 
think these blocking antibodies might 
be most important in individuals who 
have the bacteremic or disseminated 
form of the disease," Rice explained. 
"Another of the interesting aspects 
of the gonococcus is that it's ex-
tremely adaptable to humans. It has 
employed many ploys to try to trick 
humans into thinking it's not there, or 
it uses the humans' own immuno-
logic mechanisms to protect it in-
stead of protecting the human," he 
added. 
Rice's studies of the immuno-
chemical differences between the 
various strains of gonorrhea have 
turned up many interesting findings 
that are useful tools in helping ad-
vance the immunization efforts. 
"What we know is that strains that 
cause pelvic inflammatory disease 
are often very serum-sensitive (they 
are killed by normal human serum) 
while strains that reach the blood-
stream are serum-resistant," Rice 
said. "While we don't fully under-
stand what causes an organism to 
be serum-sensitive or serum-resis-
tant, we believe a serum-sensitive 
organism is capable of producing a 
local inflammatory response much 
more readily than a serum-resistant 
organism." 
For example, he continued, the 
strains that cause pelvic inflamma-
tory disease probably have the po-
tential of causing much more inflam-
mation by stimulating inflammatory 
mechanisms in the genital secretions 
and tissues they affect than do the 
gonococcal strains that cause the 
disseminated form of the disease. 
"Fewer than 30 percent of individuals 
who have the disseminated or blood-
borne form of the disease have any 
symptoms at the original site of in-
fection, usually a genital site," Rice 
said. 
"We have observed an immuno-
logic phenomenon and have dis-
sected it to learn more about how 
the host interacts with particular anti-
gens present on gonococci," Rice 
said. "With this information, we hope 
to understand not only what the im-
munologic mechanisms are and how 
they interact with the organism's anti-
gens, but we also hope to define 
these antigens and gain Insight into 
how they might be useful as vac-
cines." 
—Marjorie H. Dwyer 
Suggested Further Readings: 
1. Schoolnik, G.K. et al: Gonococci causing 
disseminated gonococcal infection are re-
sistant to the bactericidal action of normal 
human serum. J. Clin. Invest. 58: 1163-
1173, 1976. 
2. Rice, P.A. and Kasper, D.L: Characteriza-
tion of gonococcal antigens responsible for 
induction of bactericidal antibody in dissem-
inated infection: The role of gonococcal en-
dotoxins. J. Clin. Invest. 60: 1149-1158, 
1977. 
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